P250028/S003: Synergy Disc
FDA’s recorded scope: packaging materials changes and the addition of a secondary packaging configuration
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 5 FDA records to the applicant name Synergy Spine Solutions, Inc.. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 26, 2026 to Sep 17, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MJO appears in 4 of the 5 linked filings. The collection spans 2 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250028, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 357 S. Mccaslin Blvd., Suite 120, Louisville, CO, 80027. Recorded on P250028/S003, decision dated Sep 17, 2026.
Prosthesis, Intervertebral Disc; Manual Instruments Designed For Use With Total Disc Replacement Devices.
FDA’s recorded scope: packaging materials changes and the addition of a secondary packaging configuration
FDA’s recorded scope: approval for automated polishing of the mirrored surfaces of the endplates as an alternate to manual polishing at Normal Noble
FDA’s recorded scope: approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250028
FDA’s recorded scope: The Synergy Disc is indicated in skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height compared to adjacent levels. The Synergy Disc is implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Synergy Disc.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.